PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

CJC-1295 DAC — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

CJC-1295 is a tetrasubstituted form of human growth hormone-releasing factor (1-29) with an added maleimidopropionamide derivative of lysine at its C-terminus, designed to bind serum albumin after injection and so extend its plasma half-life. · pmid:15817669

History

In rats it was still present in plasma beyond 72 hours, and a CJC-1295-reactive species appeared on the serum albumin band within 15 minutes of injection. · pmid:15817669

In healthy adults a single subcutaneous injection raised mean growth hormone 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9 to 11 days; its estimated half-life was 5.8 to 8.1 days. · pmid:16352683

Identity

PubChem CID 91971820: Cjc 1295, C165H269N47O46, 3647.2 g/mol. · pubchem:91971820

CAS registry number 446262-90-4. · pubchem:91971820

Where the evidence actually sits

Emerging50%
Preclinical only50%

Proportion of the 2 claims about CJC-1295 DAC standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. (2005) · preclinicalProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. (2006) · emerging20052006

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for CJC-1295 DAC yet.

Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier

    nothing resolved on this rung

  3. Observational evidence · resolved human data at the emerging tier: thin, or contested
    • Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. · pmid 16352683 · 2006
  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work
    • Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. · pmid 15817669 · 2005

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.